Foster City, California: September 15, 2014 Diabetes Technology Society (DTS) is pleased to announce that it will hold apublic meeting regarding payer liability for funding inaccurate blood glucose monitors.This meeting, which is free to attend, is an extension of the DTS Surveillance Program for Cleared Blood Glucose Monitors, which was launched on May 20, 2014. The event will be held onNovember 5, 2014in Bethesda, Maryland, at the Residence Inn Downtown Bethesda.
After a product has been cleared by the Food and Drug Administration (FDA), there is currently no systematic post-market surveillance program available to monitor ongoing product quality. As a result, some patients diagnosed with diabetes are using blood glucose meters that do not perform to the standard of their FDA clearance. These devices can interfere with the patients ability to accurately monitor their blood glucose levels, which can lead to incorrect decisions about treatment and therefore adverse health effects.
The surveillance program will provide an independent assessment of the performance of cleared blood glucose monitors and generate information that can assist patients, payers, and healthcare providers in making informed product selections.The meeting onNovember 5, 2014will cover the outcomes and consequences for payers and patients who use products that have not maintained their performance level since being cleared by the FDA. The meeting will include perspectives from payers, clinicians, attorneys, scientists, the FDA, patients, and other members of the diabetes community.
Admission to the meeting onNovember 5, 2014is free; however, registration will be necessary to attend the event as space is limited. To register, please visit:www.diabetestechnology.org/surveillancepayersmeeting.